IBIO Latest Press Releases

-- October 13, 2026 --

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy Globe Newswire 7:00 AM

-- September 1, 2026 --

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference Globe Newswire 4:30 PM

-- August 28, 2026 --

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update Globe Newswire 7:00 AM

-- August 4, 2026 --

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer Globe Newswire 7:00 AM

-- July 1, 2026 --

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study Globe Newswire 7:00 AM

-- June 2, 2026 --

iBio to Participate in Upcoming Healthcare Investor Conferences Globe Newswire 4:01 PM

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes